logo
logo
Sign in

ASCO Abstracts 2020 | axi cel, gsk3359609, atezo bev hcc, keynote 204, ino 5401

avatar
Ankit Nigam
ASCO Abstracts 2020 | axi cel, gsk3359609, atezo bev hcc, keynote 204, ino 5401

 ASCO: axi-cel in ZUMA-1

Abstract No : 8012

Abstract Type : Oral Abstract Session

Indication : Diffused Large B-Cell Lymphoma (DLBCL)

Intervention : Yescarta

Company : Kite, a Gilead Company

Technology : CAR T Cell Therapy

Based on this limited sample size, reTx with axi-cel may have clinical efficacy, although transient, in some pts, especially those who achieve CR with 1st Tx. CAR T cell expansion and severe CRS and NEs may be attenuated at reTx. Further studies with additional pts are needed to confirm these results.

View More: https://www.delveinsight.com/asco-conference/article/zuma-1

 

GSK: Cell Therapy and Next-generation Immuno-oncology

At this year’s ASCO meeting, they will showcase presentations on investigational therapies, including belantamab mafodotin, an antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with head and neck cancer.

View More: https://www.delveinsight.com/asco-conference/article/gsk-cell-therapy-next-generation-immuno-oncology

 

IMbrave150 TRIAL of Atezolizumab

Atezo + Bev HCC

IMbrave150 demonstrated statistically significant and clinically meaningful improvement in both OS and PFS with atezo + bev vs sor in pts with unresectable HCC who have not received prior systemic therapy. Pts achieved CRs regardless of poor prognostic factors or etiology. Atezo + bev may be a practice-changing treatment for pts with unresectable HCC.

View More: https://www.delveinsight.com/asco-conference/article/imbrave150

 

ASCO: KEYNOTE-204

Abstract No : 8005

Abstract Type : Oral Abstract Session

Indication : Hodgkin’s Lymphoma (HL)

Intervention : Pembrolizumab

Company : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.

Technology : Immunocheckpoint

In pts with R/R cHL, pembro was superior to BV and demonstrated statistically significant and clinically meaningful improvement in PFS across all subgroups, with safety consistent with previous reports. Pembro monotherapy should be standard of care for this pt population with R/R/cHL.

View More: https://www.delveinsight.com/asco-conference/article/NCT02684292

 

ASCO: INO-5401 + INO-9012 with Cemiplimab

Abstract No : 2514

Abstract Type : Oral Abstract Session

Indication : Glioblastoma Multiforme

Intervention : INO-5401 and INO-9012 + Cemiplimab

Company : Inovio Pharma

Technology : T cell therapy/Monoclonal Antibody

INO-5401 + INO-9012 in combination with cemiplimab and RT/TMZ has an acceptable safety profile, is immunogenic and may show a survival advantage in patients with newly-diagnosed GBM.

View Report: https://www.delveinsight.com/asco-conference/article/NCT03491683

collect
0
avatar
Ankit Nigam
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more